Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech

Regulatory News:

At today’s Annual General Shareholders' Meeting (AGM) of Sartorius Stedim Biotech S.A. in Aubagne, France, shareholders approved the Board of Directors’ proposals by a large majority.

The AGM thus passed the resolution to pay dividends of €2.00 net per share for fiscal 2015, up from €1.30 a year earlier. The total profit distributed will therefore rise by 53.9% from €20.0 million to €30.7 million.

Moreover, the AGM approved the proposal of the Board of Directors to split by 6 the par value of each of the Company’s shares (stock split). As a result, shareholders will receive 6 new shares in exchange for each share currently held in Sartorius Stedim Biotech. This share split operation will be executed by early May without any additional costs or formalities for the shareholders and will have no impact on their rights. The stock split follows the significant increase in the share price over the past two years.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a global reach. The company employs approx. 4,200 people, and in 2015 earned sales revenue of 884.3 million euros.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160405006105/en/